What is the blend CJC‑1295 No DAC / Ipamorelin?
This blend offers two complementary peptides—CJC‑1295 No DAC (modified GHRH) and Ipamorelin (GHSR agonist)—designed for combined preclinical research on endogenous growth hormone regulation.
CJC‑1295 No DAC is a modified Growth Hormone–Releasing Hormone fragment (1–29) engineered to stimulate pulse-like GH secretion with a short half-life (approximately 30 minutes), ideal for studies involving natural temporal activation of the GH axis.
Ipamorelin is a pentapeptide ghrelin receptor agonist (sequence Aib–His–D‑2‑Nal–D‑Phe–Lys–NH₂) that selectively prompts GH release without affecting cortisol or prolactin in research models.
This dual-formulation supports synergistic GH-axis investigations: CJC‑1295 No DAC initiates hypothalamic GHRH receptor activation, while Ipamorelin enhances GH secretion via ghrelin receptor pathways—offering a near-physiological mimicry of GH pulsation in experimental frameworks.
 
Citations
Peptides.org monograph: CJC‑1295 No DAC is a short-acting GHRH(1–29) analogue (half-life ~30 min), distinct from DAC variant. 
Peptides.org: “CJC‑1295 No DAC: Modified GRF(1–29) mimics endogenous GHRH pulse, ideal for acute GH-axis studies.” 
PubChem Compound Summary for Ipamorelin (CID 9831659): sequence Aib–His–D-2-Nal–D‑Phe–Lys–NH₂; formula C₃₈H₄₉N₉O₅; MW 711.9 Da. 
Peptides.guide entry: Ipamorelin is a selective GHSR agonist promoting GH release without cortisol/prolactin release, used in muscle growth and body composition research.